VBL

Notable Labs Closes Merger Transaction With VBL Therapeutics

Retrieved on: 
Monday, October 16, 2023
Machine learning, Founders Fund, Association of British HealthTech Industries, Apoptosis, Builder, United States Medical Licensing Examination, AML, VBL, Cancer, Induced cell cycle arrest, CUSIP, Therapy, PLK1, Acute myeloid leukemia, First Round Capital, Y Combinator, Patient, Security (finance), Pharmaceutical industry, Notability, Volasertib

- Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund -

Key Points: 
  • - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund -
    FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the completion of its merger transaction with VBL Therapeutics (“VBL”) (Nasdaq: VBLT) and associated financing.
  • “This is an important milestone for Notable as we continue to advance the demonstrated value of the PPMP,” said Thomas Bock, M.D., Chief Executive Officer of Notable.
  • “The merger will add additional capital to accelerate our continued development of Volasertib for the treatment of AML in PPMP-predicted responding patients.
  • PPMP has guided Notable in the selection and development of two clinical-stage therapeutic candidates in platform-predicted responding patients with AML.

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

Retrieved on: 
Thursday, October 12, 2023
Ticker, Effectiveness, Combination company, VBL, Therapy, Pharmaceutical industry, Airline, Mergers and acquisitions

MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and special meeting (the “Meeting”) which took place today, October 12, 2023.

Key Points: 
  • Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions
    MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and special meeting (the “Meeting”) which took place today, October 12, 2023.
  • Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger.
  • The Merger is expected to close on or around October 16, 2023.
  • After completion of the Merger, VBL will be renamed “Notable Labs, Ltd.” and is expected to trade on The Nasdaq Capital Market under the symbol “NTBL” on or around October 17, 2023.

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

Retrieved on: 
Wednesday, October 4, 2023
Communication, Plan, Proxy, AND, Meeting, Notability, The Meeting, Person, Tripura Merger Agreement, BEST, Prospectus, VBL, Annual report, ITS, Form, FORM, NIS, Security (finance), Therapy, Broker, Mergers and acquisitions

MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023.

Key Points: 
  • MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023.
  • VBL Ordinary Shares are currently listed on The Nasdaq Capital Market under the symbol “VBLT”.
  • After completion of the Merger, VBL is expected to be renamed “Notable Labs, Ltd.” and trade on The Nasdaq Capital Market under the symbol “NTBL”.
  • THE VBL BOARD OF DIRECTORS RECOMMENDS THAT VBL SHAREHOLDERS VOTE “FOR” EACH SUCH PROPOSAL.

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

Retrieved on: 
Wednesday, September 6, 2023
Form S-4, Notability, Prospectus, VBL, Patient, Form, Therapy, Proxy, Airline, Pharmaceutical industry

MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).

Key Points: 
  • Merger with Notable expected to close in mid-October, subject to shareholder approval
    Special shareholder meeting scheduled for October 12, 2023
    MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).
  • The definitive merger agreement between VBL and Notable was announced on February 23, 2023 and is expected to close in mid-October 2023, subject to customary closing conditions, including approval of the merger by VBL’s shareholders.
  • The registration statement contains a proxy statement / prospectus / information statement in connection with the merger.
  • “Having our registration statement on Form S-4 declared effective by the SEC is an important step towards the closing of our previously announced merger with Notable,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL.

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, EU4, DNA, Bevacizumab, Malignancy, Radiation, Temozolomide, GBM, Survivin, Neoplasm, Epidemiology, Survival, Forest Law Enforcement and Governance Program, Cancer, Genentech, Immunotherapy, USD, Incidence, VEGF, Health insurance coverage in the United States, Congress of Neurological Surgeons, VBL, AANS, American Association of Neurological Surgeons, Patient, Patent, Ofranergene obadenovec, IDH1, Growth, Merck, FDA, Therapy, Disease, Mobile phone, Health care, Pharmaceutical industry, Glioma

The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Key Points: 
  • The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.
  • Epidemiology: Glioma's epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032.
  • The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent.
  • Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies.

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Cancer, Research, Sale, VBL, Patient, Form, Therapy, Capital loss, Pharmaceutical industry, Cryptocurrency

MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • “We continue to make good progress towards the closing of our previously announced merger with Notable,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL.
  • “We believe the proposed merger represents the best path forward for the shareholders of both companies and for patients.
  • Although not required by Israeli law, shareholders will be asked to provide a non-binding advisory vote at the VBL special meeting.
  • On June 30, 2023, VBL had cash and cash equivalents of $24.3 million.

Timeless Vapes Shoots And Scores In Partnership With Venice Basketball League

Retrieved on: 
Wednesday, July 19, 2023
DNA, Collection, KVBL, Partnership, Timeless, Culture, Num ansom, Hoop Dreams, Athlete, VBL, Sport, Imagination

SCOTTSDALE, Ariz., July 19, 2023 /PRNewswire/ -- Timeless Vapes ("Timeless" or the "Company"), a lifestyle brand leading the way in cannabis culture, today partnered with the Venice Basketball League (VBL), a live event and media brand building community through basketball, to announce the Timeless x VeniceBall Mosaic Collection. The exclusive collection celebrates the league's rich history through uniquely designed gym bags, SUPLMNT water bottles, and the Company's signature vaporizer flip case and battery combos. Timeless has a frequent presence at VBL games, and will donate a portion of the proceeds from the collection to the VBL's philanthropic initiatives including HOOPBUS.

Key Points: 
  • "Venice Basketball League views basketball as a source of community and Timeless believes cannabis is a connective force bringing together individuals from all walks of life," said Rocky Huang, Founder of Timeless Vapes.
  • Ansom's world-renowned summer basketball league has won four of its own world championships, built courts in underserved communities, and launched several philanthropic initiatives including the HOOPBUS and Kids Venice Basketball League (KVBL).
  • "The purpose of starting the Venice Basketball League was to create a home and stage for basketball players to be recognized for the gift and talent that we have," said Nick Ansom, founder of the Venice Basketball League.
  • The 2023 Venice Basketball League regular season is underway with the support of countless world-class athletes and teams, including Team Timeless .

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
Aleph Farms, Cancer, Research, Notability, Sale, VBL, Patient, Form, Therapy, Pharmaceutical industry

MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  • “We believe the proposed merger with Notable represents the best path forward for shareholders of both companies and patients.
  • The proceeds from the facility sale will remain in VBL for the benefit of shareholders and the future combined company.
  • On March 31, 2023, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $26.5 million.

VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 14, 2023
Cancer, Research, Founders Fund, Builder, Sale, Therapy, Y Combinator, Acute myeloid leukemia, Patient, Notability, VBL, Nanocarriers, First Round Capital, AML, Pharmaceutical industry, Cryptocurrency

MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.
  • Results from a new clinical validation study of Notable’s PPMP will be presented at a medical conference in the second quarter of 2023.
  • On December 31, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $21.1 million.
  • In addition, in March 2023, VBL received $7.1 million in proceeds from the sale of VBL’s Modi’in manufacturing facility and certain related assets.

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

Retrieved on: 
Thursday, March 9, 2023
Therapy, VBL, Sale, Agreement, Plan, Aleph Farms, Pharmaceutical industry, Management

MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.

Key Points: 
  • MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.
  • VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023.
  • “We are pleased to announce the closing of the sale of our facility, consistent with our plans to unlock value from our assets and maximize shareholder value,” said Dror Harats, M.D., Chief Executive Officer of VBL.